On November 26, 2012, Transcept Pharmaceuticals, Inc. ("Transcept") issued a press release announcing that Purdue Pharmaceutical Products, L.P. ("Purdue"), Transcept's U.S. commercialization partner for Intermezzo® (zolpidem tartrate) sublingual tablet C-IV, will be launching a national direct-to-consumer ("DTC") promotional campaign, including digital, print and television advertising to support Intermezzo commercialization (the "DTC Program").

Transcept also announced that Purdue has committed $19 million to the DTC Program, and Transcept plans to provide an additional $10 million. The $29 million DTC Program will be primarily executed during the first six months of 2013. Transcept's $10 million investment will be paid within 10 calendar days of November 26, 2012.

To reinforce the DTC Program, Purdue plans to utilize for the first time its established analgesic sales force, which consists of approximately 525 sales representatives, to promote Intermezzo to primary care prescribers and certain medical specialists. Purdue will continue to market Intermezzo to psychiatrists and other specialty prescribers with a specialty sales force of approximately 90 sales representatives who are exclusively devoted to Intermezzo.

A copy of the press release, dated November 26, 2012, is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The following Exhibit is filed as part of this Current Report on Form 8-K.

(d) Exhibits

Exhibit Number                                  Description

99.1                   Press Release, "Transcept Pharmaceuticals Announces Broadened
                       Intermezzo® Commercialization Strategy Including Initiation
                       of a Direct to Consumer Advertising Campaign by Purdue
                       Pharma" dated November 26, 2012.